Javascript must be enabled to continue!
Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney
View through CrossRef
Abstract
Background
The inhibition of dipeptidyl peptidase (DPP) IV shows protective effects on tissue injury of the heart, lung, and kidney. Forkhead box O (FoxO) transcriptional factors regulate cellular differentiation, growth, survival, the cell cycle, metabolism, and oxidative stress. The aims of this study were to investigate whether the DPP IV inhibitor sitagliptin could attenuate kidney injury and to evaluate the status of FoxO3a signaling in the rat remnant kidney model.
Methods
Rats were received two-step surgery of 5/6 renal mass reduction and fed on an oral dose of 200 mg/kg/day sitagliptin for 8 weeks. Before and after the administration of sitagliptin, physiologic parameters were measured. After 8 weeks of treatment, the kidneys were harvested.
Results
The sitagliptin treatment attenuated renal dysfunction. A histological evaluation revealed that glomerulosclerosis and tubulointerstitial injury were significantly decreased by sitagliptin. Sitagliptin decreased DPP IV activity and increased the renal expression of glucagon-like peptide-1 receptor (GLP-1R). The subtotal nephrectomy led to the activation of phosphatidylinositol 3-kinase (PI3K)-Akt and FoxO3a phosphorylation, whereas sitagliptin treatment reversed these changes, resulting in PI3K-Akt pathway inactivation and FoxO3a dephosphorylation. The renal expression of catalase was increased and the phosphorylation of c-Jun N-terminal kinase (JNK) was decreased by sitagliptin. Sitagliptin treatment reduced apoptosis by decreasing cleaved caspase-3 and −9 and Bax levels and decreased macrophage infiltration.
Conclusions
In rat remnant kidneys, DPP IV inhibitor attenuated renal dysfunction and structural damage. A reduction of apoptosis, inflammation and an increase of antioxidant could be suggested as a renoprotective mechanism together with the activation of FoxO3a signaling. Therefore, DPP IV inhibitors might provide a promising approach for treating CKD, but their application in clinical practice remains to be investigated.
Springer Science and Business Media LLC
Title: Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney
Description:
Abstract
Background
The inhibition of dipeptidyl peptidase (DPP) IV shows protective effects on tissue injury of the heart, lung, and kidney.
Forkhead box O (FoxO) transcriptional factors regulate cellular differentiation, growth, survival, the cell cycle, metabolism, and oxidative stress.
The aims of this study were to investigate whether the DPP IV inhibitor sitagliptin could attenuate kidney injury and to evaluate the status of FoxO3a signaling in the rat remnant kidney model.
Methods
Rats were received two-step surgery of 5/6 renal mass reduction and fed on an oral dose of 200 mg/kg/day sitagliptin for 8 weeks.
Before and after the administration of sitagliptin, physiologic parameters were measured.
After 8 weeks of treatment, the kidneys were harvested.
Results
The sitagliptin treatment attenuated renal dysfunction.
A histological evaluation revealed that glomerulosclerosis and tubulointerstitial injury were significantly decreased by sitagliptin.
Sitagliptin decreased DPP IV activity and increased the renal expression of glucagon-like peptide-1 receptor (GLP-1R).
The subtotal nephrectomy led to the activation of phosphatidylinositol 3-kinase (PI3K)-Akt and FoxO3a phosphorylation, whereas sitagliptin treatment reversed these changes, resulting in PI3K-Akt pathway inactivation and FoxO3a dephosphorylation.
The renal expression of catalase was increased and the phosphorylation of c-Jun N-terminal kinase (JNK) was decreased by sitagliptin.
Sitagliptin treatment reduced apoptosis by decreasing cleaved caspase-3 and −9 and Bax levels and decreased macrophage infiltration.
Conclusions
In rat remnant kidneys, DPP IV inhibitor attenuated renal dysfunction and structural damage.
A reduction of apoptosis, inflammation and an increase of antioxidant could be suggested as a renoprotective mechanism together with the activation of FoxO3a signaling.
Therefore, DPP IV inhibitors might provide a promising approach for treating CKD, but their application in clinical practice remains to be investigated.
Related Results
Screening of Actinomycetes for dipeptidyl peptidase-4 inhibitors production
Screening of Actinomycetes for dipeptidyl peptidase-4 inhibitors production
Hyperglycemia or high blood sugar is the most common cause of diabetes. Diabetes mellitus is the most common and fastest growing disease in the world. One of the therapies to treat...
Runahead threads
Runahead threads
Los temas de investigación sobre multithreading han ganado mucho interés en la arquitectura de computadores con la aparición de procesadores multihilo y multinucleo. Los procesador...
Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors
Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors
AbstractObjectiveSulfonylureas and dipeptidyl peptidase‐4 inhibitors have a multidirectional effect on pancreatic cells. We aimed to evaluate the effects of these drugs on β‐ and α...
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
Rethinking Anticoagulation in Kidney Disease and Kidney Transplantation
BackgroundA clinical dilemma exists in patients with CKD, ESKD, and after kidney transplantation, as they face concurrent risks of both thromboembolic and hemorrhagic complications...
Aspects of the Remnant Concept in the Gospel of Matthew
Aspects of the Remnant Concept in the Gospel of Matthew
Only some aspects of the remnant concept in the christology and ecclesiology of Matthew are dealt with in this dissertation. Special attention is given to the evangelist's distinct...
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
PROCEEDINGS OF THE AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL PHARMACOLOGISTS
1.Effect of chronic haloperidol treatment on D‐2 receptors labelled by (3H)‐spiperone in homogenates of rat corpus striatum. A. L. Gundlach, D. J. de Vries and P. M. Beart2.The eff...
Residual Cholesterol and Residual Inflammation Risk Associated with In-Stent Restenosis
Residual Cholesterol and Residual Inflammation Risk Associated with In-Stent Restenosis
Abstract
Background
Remnant cholesterol (remnant-C) and inflammation are considered risk factors for in-stent restenosis (ISR). We evaluate the combined impact of remnant-...
Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population
Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population
ObjectiveHigh remnant cholesterol concentrations are associated with high risk of ischemic heart disease, but whether this is also the case for ischemic stroke is unknown. We teste...

